Pirtobrutinib Decreased the Emergence of BTK C481 Clones in Patients With CLL
Findings from the phase 1/2 BRUIN trial of show a distinct genetic evolution in patients with B-cell malignancies. However, the baseline BTK mutations did not impede pirtobrutinib’s effectiveness.
Source: targetedonc.com